ALNY – Alnylam Pharmaceuticals, Inc.
Float Short %
3.17
Margin Of Safety %
Put/Call OI Ratio
1.21
EPS Next Q Diff
2.61
EPS Last/This Y
5.92
EPS This/Next Y
5.29
Price
465.73
Target Price
457.28
Analyst Recom
1.69
Performance Q
52.92
Relative Volume
0.57
Beta
0.36
Ticker: ALNY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | ALNY | 449.19 | 1.16 | 0.36 | 19185 |
| 2025-08-18 | ALNY | 457.8 | 1.11 | 0.72 | 14998 |
| 2025-08-19 | ALNY | 458.33 | 1.09 | 0.38 | 15495 |
| 2025-08-20 | ALNY | 459.98 | 1.08 | 0.88 | 15679 |
| 2025-08-21 | ALNY | 467.59 | 1.08 | 1.88 | 16233 |
| 2025-08-22 | ALNY | 454.31 | 1.10 | 0.80 | 16687 |
| 2025-08-25 | ALNY | 443.59 | 1.12 | 0.63 | 17260 |
| 2025-08-26 | ALNY | 451.12 | 1.11 | 5.59 | 17378 |
| 2025-08-27 | ALNY | 454.04 | 1.13 | 1.89 | 17589 |
| 2025-08-28 | ALNY | 452.39 | 1.14 | 29.05 | 18143 |
| 2025-08-29 | ALNY | 447 | 1.17 | 1.80 | 18453 |
| 2025-09-02 | ALNY | 446.83 | 1.20 | 0.54 | 18696 |
| 2025-09-03 | ALNY | 447.23 | 1.22 | 2.41 | 18879 |
| 2025-09-04 | ALNY | 453.46 | 1.23 | 1.54 | 19336 |
| 2025-09-05 | ALNY | 452.02 | 1.22 | 3.86 | 19564 |
| 2025-09-08 | ALNY | 455.02 | 1.21 | 1.74 | 19501 |
| 2025-09-09 | ALNY | 482.79 | 1.22 | 0.70 | 19848 |
| 2025-09-10 | ALNY | 469.12 | 1.20 | 1.34 | 20516 |
| 2025-09-11 | ALNY | 468.5 | 1.21 | 0.74 | 21098 |
| 2025-09-12 | ALNY | 465.77 | 1.21 | 0.70 | 21140 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | ALNY | 449.14 | 387.4 | 651.4 | 3.92 |
| 2025-08-18 | ALNY | 456.87 | 387.4 | 652.8 | 3.92 |
| 2025-08-19 | ALNY | 458.28 | 387.4 | 646.5 | 3.92 |
| 2025-08-20 | ALNY | 458.46 | 387.4 | 645.4 | 3.92 |
| 2025-08-21 | ALNY | 467.59 | 387.4 | 653.9 | 3.92 |
| 2025-08-22 | ALNY | 454.41 | 387.4 | 633.2 | 3.92 |
| 2025-08-25 | ALNY | 443.60 | 387.4 | 635.0 | 3.92 |
| 2025-08-26 | ALNY | 451.20 | 387.4 | 652.5 | 3.92 |
| 2025-08-27 | ALNY | 454.00 | 387.4 | 647.9 | 3.92 |
| 2025-08-28 | ALNY | 452.20 | 387.4 | 643.3 | 3.92 |
| 2025-08-29 | ALNY | 446.31 | 387.4 | 639.5 | 3.92 |
| 2025-09-02 | ALNY | 446.82 | 387.4 | 645.5 | 3.92 |
| 2025-09-03 | ALNY | 447.33 | 387.4 | 1022.4 | 3.92 |
| 2025-09-04 | ALNY | 453.57 | 387.4 | 1033.0 | 3.92 |
| 2025-09-05 | ALNY | 452.00 | 386.6 | 1019.1 | 3.92 |
| 2025-09-08 | ALNY | 455.03 | 386.6 | 1027.3 | 3.92 |
| 2025-09-09 | ALNY | 482.42 | 377.9 | 1070.9 | 3.74 |
| 2025-09-10 | ALNY | 469.21 | 377.9 | 1000.0 | 3.74 |
| 2025-09-11 | ALNY | 468.58 | 377.9 | 1020.6 | 3.74 |
| 2025-09-12 | ALNY | 465.73 | 377.9 | 1016.9 | 3.74 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | ALNY | -2.30 | 1.04 | 2.58 |
| 2025-08-18 | ALNY | -2.30 | 0.58 | 2.58 |
| 2025-08-19 | ALNY | -2.61 | 0.58 | 2.58 |
| 2025-08-20 | ALNY | -2.69 | 0.58 | 2.58 |
| 2025-08-21 | ALNY | -2.69 | 0.58 | 2.58 |
| 2025-08-22 | ALNY | -2.69 | 0.58 | 2.58 |
| 2025-08-25 | ALNY | -2.69 | 2.02 | 2.58 |
| 2025-08-26 | ALNY | -2.69 | 2.02 | 2.58 |
| 2025-08-27 | ALNY | -2.69 | 2.02 | 2.73 |
| 2025-08-28 | ALNY | -2.69 | 2.02 | 2.73 |
| 2025-08-29 | ALNY | -2.69 | 2.02 | 2.73 |
| 2025-09-02 | ALNY | -2.75 | 2.04 | 2.73 |
| 2025-09-03 | ALNY | -2.75 | 2.04 | 2.73 |
| 2025-09-04 | ALNY | -2.65 | 2.04 | 2.73 |
| 2025-09-05 | ALNY | -2.65 | 2.04 | 2.73 |
| 2025-09-08 | ALNY | -2.47 | 2.04 | 2.73 |
| 2025-09-09 | ALNY | -2.47 | 2.04 | 2.73 |
| 2025-09-10 | ALNY | -2.47 | 2.04 | 2.73 |
| 2025-09-11 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-12 | ALNY | -2.77 | 2.04 | 3.17 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.51
Avg. EPS Est. Current Quarter
1.39
Avg. EPS Est. Next Quarter
2.1
Insider Transactions
-2.77
Institutional Transactions
2.04
Beta
0.36
Average Sales Estimate Current Quarter
947
Average Sales Estimate Next Quarter
1192
Fair Value
Quality Score
41
Growth Score
49
Sentiment Score
88
Actual DrawDown %
3.8
Max Drawdown 5-Year %
-42.5
Target Price
457.28
P/E
Forward P/E
78.95
PEG
P/S
24.8
P/B
243.51
P/Free Cash Flow
EPS
-2.47
Average EPS Est. Cur. Y
3.74
EPS Next Y. (Est.)
9.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-12.96
Relative Volume
0.57
Return on Equity vs Sector %
-152.2
Return on Equity vs Industry %
-139.1
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.16
EBIT Estimation
1016.9
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading